WNT2B: comparative integromics and clinical applications (Review).

Area of Science:

• Genetics and Developmental Biology
• Molecular Oncology
• Stem Cell Biology

Background:

• Human WNT2B (WNT13) was cloned and characterized in 1996, with subsequent identification of orthologs across various species.
• Comparative integromics analyses reveal paralogous genomic regions and conserved regulatory elements (E box, CCAAT box) in WNT2B promoters.
• Alternative promoter usage results in two WNT2B splicing variants: a secreted form (isoform 1) and a conserved transmembrane form (isoform 2).

Purpose of the Study:

• To review comparative integromics analyses of WNT2B.
• To explore the clinical applications of WNT2B.
• To elucidate the evolutionary conservation and functional significance of WNT2B isoforms.

Main Methods:

• Integromics analysis of WNT2B and its paralogs.
• Characterization of WNT2B splicing variants and orthologs.
• Review of existing literature on WNT2B function and clinical relevance.

Main Results:

• WNT2B isoform 2, the major transcript, is evolutionarily conserved and possesses a transmembrane domain and RGD motif.
• WNT2B isoform 2 functions as a canonical WNT, regulating cell fate via beta-catenin/TCF and SNAIL/EMT pathways.
• WNT2B acts as a stem cell factor in embryogenesis and is implicated in gastric, esophageal, and skin cancers.

Conclusions:

• WNT2B isoform 2 is a key regulator of cell fate and development.
• Targeted therapies using anti-WNT2B antibodies or inhibitors show promise for cancer treatment.
• WNT2B-based strategies are valuable for stem cell expansion in regenerative medicine and tissue engineering.